Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Liabilities and Shareholders Equity (2020 - 2025)

RxSight (RXST) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $311.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 2.12% year-over-year to $311.8 million, compared with a TTM value of $1.2 billion through Dec 2025, up 11.16%, and an annual FY2025 reading of $311.8 million, down 2.12% over the prior year.
  • Liabilities and Shareholders Equity was $311.8 million for Q4 2025 at RxSight, up from $308.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $318.6 million in Q4 2024 and bottomed at $94.9 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $224.4 million, with a median of $195.3 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 91.43% in 2021, then fell 23.57% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $192.7 million in 2021, then dropped by 22.08% to $150.2 million in 2022, then rose by 21.57% to $182.5 million in 2023, then surged by 74.51% to $318.6 million in 2024, then decreased by 2.12% to $311.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RXST at $311.8 million in Q4 2025, $308.5 million in Q3 2025, and $309.0 million in Q2 2025.